SiccaRapid™ is a non-invasive PoCT (Point-of-Care Testing) that translates laboratory proteomics into a rapid clinical device. Powered by a cross-validated multiplex biomarker panel (0.8 AUC), our microfluidic kit is engineered for rapid same-visit clinical turnaround (Current prototype: 30 mins, with active optimization towards 10 mins detection time). Beyond initial diagnosis, it enables precise longitudinal tracking of molecular tear changes over time, allowing clinicians to objectively measure treatment response and eliminate trial-and-error prescribing.
Dry Eye Disease (DED) affects hundreds of millions worldwide, and conventional eye exams rely heavily on the clinician’s subjective interpretation, with no clinical gold standard for diagnosis. These tests also often fail to differentiate between the two main root causes of DED, the evaporative and aqueous-deficient subtypes. This forces a trial-and-error treatment approach that delays patient relief.
Primary Function: To analyze a tear sample and differentiate DED and its subtypes in less than 30 minutes, and to track molecular tear changes over time so clinicians can objectively measure treatment response and eliminate trial-and-error prescribing.
Core Technologies:
Key Advantages:
PolyU InternationalFutureChallenge(Nanjing Region)- Best Innovation Award
Prof. Thomas LAM, Principal Investigator, CEVR
Dr. William NGO, Principal Investigator, CEVR
Dr. Jimmy CHEUNG, Visiting Scientist, CEVR
Dr. Jimmy CHEUNG, Visiting Scientist, CEVR
No related ventures available in this category.